Proactive Investors - Run By Investors For Investors

TG Therapeutics rallies after reporting progress in trial of treatment for non-Hodgkin’s lymphoma

A paper showed an overall response rate of 84% for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma and 68% for non-Hodgkin’s lymphoma
A collection of pills
The triple-combination therapy was well-tolerated, according to TG Therapeutics

TG Therapeutics Inc (NASDAQ:TGTX) rallied Wednesday after announcing the publication of results from the Phase 1 trial of a combination of three drugs for the treatment of lymphoma.

A paper published in The Lancet Haematology showed an overall response rate of 84% for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, according to New York-based TG Therapeutics.

Shares of the company climbed 7% to $4.46 in Wednesday’s premarket trading.

READ: TG Therapeutics receives Breakthrough Therapy Designation for lymphoma treatment Umbralisib

Among patients with non-Hodgkin’s lymphoma, 68% achieved a response. The triple combination was well-tolerated with a “manageable adverse-event profile,” according to the company.

The drugs in the combination are ublituximab (TG-1101), the company’s anti-CD20 monoclonal antibody; umbralisib, its oral, once-daily PI3K delta inhibitor; and ibrutinib, the oral Bruton's tyrosine kinase (BTK) inhibitor.

“The data included in this publication further support our goal of developing a proprietary triple combination of ublituximab, umbralisib and our own BTK inhibitor,” CEO Michael S. Weiss said in a statement.

The company plans to start clinical trials for the BTK inhibitor, known as TG-1701, later this year.

Contact Dennis Fitzgerald at [email protected]

View full TGTX profile View Profile

TG Therapeutics Inc Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use